F8 and hemophilia A: In addition, we previously demonstrated efficacy with these cells in an ex vivo gene delivery strategy in murine37 and canine30 models of hemophilia A. We have not yet evaluated the CO-N6 transgene in our ex vivo delivery strategy in hemophilia A dogs as the initial trial with the BDD FVIII transgene was associated with an anti-FVIII immune response.